Table Of Content

SUBJECT INDEX WPtTT ... yeclie sain ‘ 593 Comprehensive Sickle Cell Centers 2089 Asian populations hospital satisfaction with 2S:109 Chinese sotnesse 2 . 471, 529, 1871 role in transfusion recipient care 28:101, 104 Eastern ¥ 1948(1 Blood collection agencies 385, 729, 763 Thai 1803, 2315 Blood component therapy. See also Cellular therapy products; specific Aspirin, PLT function and . 1 4S:206, 67 blood components AS.TEC204 .... meee , . 241 bar code labeling Atrial natriiuretic peptice blood data collection reports Austria Blood conservation algorithm Autoantibodies Blood culture systems with alloantibodies automated, predicting improvement of LAT crossmatch ‘ . 290 BacT/ALERT (See BacT/ALERT culture system RBC 2189 comparisons Autoimmune hemolytic anemia ..... 50, 1290, 1902 false-negative rates Autoimmune thrombocytopenia .... 499 time-dependence Autoimmune thrombocytopenic purpura 2161 two-bottle Autologous tissue oversight 194 zero tolerance Autologous transplantation 215 Blood data collection reports Avian influenza A . 1080 BloodGen project Blood groups. See also specific blood groups antibodies 3aboon PLTs 418:206 DNA typing 1S:10 BacT/ALERT culture system expression systems 18:85 AABB PLT criteria 1340(f genotyping 7, 64, 95 failure 1381, 1391 PCR-SSP typing 18:54 time dependence 2044 Blood industry 173 Bacterial contamination. See Platelet contamination Blood inventory management 28:190 Bacterial detection Blood loss. See Bleeding in asymptomatic donor Blood safety. See Safety concentration effects Blood salvage, postoperative culture-based (See BacT/ALERT culture system Blood supply systems access, poverty and doubling sample volume donation promotion strategies in PLT concentrates impact of demographic changes proficiency testing for influenza pandemic Bacterial inactivation. See Pathogen inactivation shortages Bar code technology 28:120S 7 in United States Bayer analyzer Blood utilization B-cell lymphomas changing clinician's transfusion practices BeadChip array 3 computer-assisted system review Beckman Coulter . in elective surgery Behavioral science, donor recruitment/retention and 1999 in Germany Belgium 21 optitmhroiughz beinchnmargki ng Benchmarking 1468 patterns in elderly Bernard-Soulier syndrome 103 reducing bHCG 788 Blood volume calculation, for pediatric transfusion Biofilms 1143 Bone fractures BioMérieux system 2044 Bone marrow product quality control Bleeding Bone marrow transplantation, allogeneic after HSCT 801 BPA bottle in elective surgery 1468 BPN bottle H12-PEG-polyAlb treatment 1254 Bradykinin massive 2S:176 Brazilians nonsurgical bleeding diathesis 4S:206, 1744(I donors, HIV risk and antiretrdoruvg iresrisatalnc e Bleeding time, hypothermia and 4S:206 profiles Blood bank Kell blood group antigens education curriculum content proposal 1930 Knops blood group haplotypes sickle cell patient management 2089 newborns, platelet alloimmunizatioannd N1 Blood-borne infections. See also Transfusion-transmitted infections Buffy coats specific infections Butane-1,4-diol cooling plates influenza viremia 1071 B’-alleles SFV Blood center-hospital relationship Cc blood inventory management Cadaver blood clinical interactioannd services 7 Calorimetry, of contaminated platelets 1643 in England and North Wales 5 Canadia Blood Services hemovigilance i anti-HBc testing 1809 management 2 7 bacterial detection in PLTs 121 Pittsburgh centralized transfusion model l consensus development 2176(t supply chain management IVIG usage 2072 Sweden : 2S:169 predonation screening 949(L), 1595, 1794 in treating massively bleeding patients 2S:176 suspected TT-HCV 1534 Blood centers. See also Blood center-hospital relationship Tl residial risk 316 Volume 47, December 2007 TRANSFUSION 2361 SUBJECT INDEX Cancer for physician order entry 228 allogenic RBC transfusions ....... sntvinns 1691 for self-interviews . 1595 lymphomas 199, 1447 OM.TEC cell separator 824, 987, 2297 andida albicans ; . 1405, 1643 onfounder variable hypothesis 1945(1 ardiac surgery 8, 1739(L), 2081 ongenital haptoglobin deficiency ardiomyocyte-like cells 280 onsensus development 2176(5 ardioprotection ‘ 341 ONSORT guidelines 2(E aspase activation 1212 onsortium for Blood Group Genes 18:98 atheter-related thrombosis 1837 ontrolled-rate freezing 5 2902 BF/NF-Y . 23230 ord blood D34+ ... saceus 817, 2153 for autologous RBC transfusion D44 antigens 1306 CD133+ cells D20+ B-cell NHI ‘ 1447 HSC recovery D34+ cells transplant tolerance collection . : 1230, 1851, 2207 oronary artery bypass graft content in UBC units for cryopreservation ost, iron chelation therapy noncompliance selection ost-effectiveness, of iron chelation therapy yield prediction PP D133+ cells RAM D4 count reutzfeldt-Jacob disease, variant 1418, 2025 D11+c precursor dendritic cells 1241 romer blood group system D47 expression 1725 rossmatch, LAT D44 gene 1306 ross-reactivity D14+ monocytes 1241, 2297 ROV D123+ precursor dendritic cells 241 ryopreservation D3 T-cell depletion 2134 TCLAG D8+ T cells, CMV-specific 2143 Ls ell culture technique 136 ultural values ell-Dyn 4000 ...... 651 yclophosphamide ellular therapy products ytokines bar code labeling ytomegalovirus HHV-8 screening implementation plan radiofrequency identification D alleles, weak 1350 regulation of MHC expression D antigen 1S:17, 1616 terminology and labeling standards 319 DAT FU-GM ' 817 Dce haplotype hagas disease ” 40 Death hemiluminescence assays 686 early, in AMI hemokines. ......... 154 intrauterine hemotaxis .. 395 TA-GVHD hemotherapy-based PBPC mobilization 2 17, 2153 transplant-related hildren. See Pediatric patients DeBakey roller pump himerism Decay-accelerating factor hinese population Deferiprone 919 1-inhibitor deficiency Deferoxamine 919 itrate anticoagulant system Deferrals, donor 1514, 1990 lassification, acute transfusion reaction 621 Deglycerolization 680, 2242 linical trials Delayed hemolytic transfusion reactions design and reporting 2(k Deletions intention-to-treat principle 973, 1946(1 genomic randomization in 1753 haptoglobin-gene treatment allocation 2187 RHD gene LI seule secs 361 DEL phenotype MV-specific cytotoxic T cells .... 2143 DEL variant 8) oagulation factors. See also specific coagulation factors Demographics, donot 1862, 1871 in apheresis and leukodepleted WB-plasma 160 Dendritic cells 1241, 2290 in irradiated FFP . 1658 Denmark 2017 storage generated micropartic les 1880 Desferrioxamine 175 1(k warm storage of WB , ' 2050 DHPLC analysis 858 oagulopathies . is 748(L), 749(1 Diabetes mellitus, alloimmunization risk 2066 obas MPX test vie saab ‘ 1783 Differential in-gel electrophoresis 1221 OBE Spectra plateletpheresis device 1241, 1943(1 Dimetyl sulfoxide-resistant filter, for cryopreservation 1033 ohort studies ... _ . - 115 Disulfide compounds 290 old agglutinins 361, 499 DMSO 1268, 2202 ompliance 1919, 2169(1 DNA analysis omplications. See Adverse events Dombrock blood group 1356 ompocool , : . 2038 Duffy blood group 18:28 ompoCool-WB . , ciecsions 2038 high-throughput 736 UID cc starcscanstiiaacsdekednnsnintconnicens . 955 Kell blood group 18:32 omprehensive Sickle Cell Centers oS Kidd blood group 18:2 omputer -assisted systems Kx blood group for blood utilization review 2S8:142 limitations 2362 TRANSFUSION Volume 47, December 2007 SUBJECT INDEX novel variations E Iderly blood use patterns 2 parvovirus B19 I lective surgery 146 1503 QA for reagent RBCs 18:73 I LISA 1630 RBC antigen phenotype 18:60 I lutra cell separator 2290 Rh blood group system 18:17, 1337(1 I merging Infections Network 1206 DOB allele 1356 I mily Cooley Award Lecture 2006 Documentation 568, 763 I ndothelial-like cells Dombrock blood group 1356 I ngland, blood center-hospital relationship Donath-Landsteiner antibody 1902 I ngraftment prediction Donation. See also Donors I quilibrium freezing 935 autologous I rythrocytapheresis 1002 employer-organized 1871 Escherichia coli 1896 improving 4102 I SHAP 1447 intention 1006 |E ucaryote recombinant Lu 1630 National Marrow Donor Program L1O1(I urope opinions 799 blood supply pediatric elective surgery 1503 travel deferrals repeated 1607, 1862 vidence-basex 1 medicine symptoms 995 xon 8 deletion vasovagal reactions xtracorporeal blood volume Donation archives L1L10(E xtracorporeal bypass Donor lymphocyte chimerism Donor-recipient repositories LLIOCE F Donors y receptor-mediated phagocytosis altruism 1862, 1999 DA asymptomatic detection of bacterial contamination in plateletpheresis guidance attention role in immunohematology srazilian, HIV risk in tissue recall Chinese, residual risk for HCV and HIV ebrile nonhemolytic transfusion reactions cytomegalovirus DNA in “males, alloimmunization risk ) rritin deferrals “tal bovine serum exclusionary factors tal Cell Count kit emale, TRALI risk and tomaternal alloimmune thrombocytopenia irst-time tomaternal hemorrhage French, anti-LCMV in tus genotyping operational issues 18:69 blood group genotyping improving health profile 201 PLTs intention to redonate 1006 RBCs in maternal blood male 99 mass-scale genotyping ADAMTS13 in Pakistani compliance with transfusion guidelines parvovirus B19 DNA levels irradiated, coagulation system in platelet counts 1601 for mild coagulation abnormalities potential U.S. pool 1180 proactive administration for AAA promotion strategies for 160 ibrinogen y-chain dodecapeptide rare blood "SA ibrinolytic system, in irradiated FFP RBC antigen phenotype by DNA analysis 18:60 ilgrastim recruitment 1999 low cytometry repeat 1514, 1862 luorescence-activated cell sorting retention of 995, 1999 ollicular lymphoma sickle trait rance, anesthesia-related deaths in Swedish reezing with nonpenetrating polyme rs symptoms resnius COM.TEC cell separator. See COM.TEC cell separator rRALI, management of FUT2 alleles, novel 1369 vasovagal reactions FUT2 gene 1369 weak D+ \\ 160 whole-blood 67, 890, 895 880 Double-RBC collection 995, 1002, 2025 g | DPG 2050 160 DRB3+0101 Drug-induced immune hemolytic anemia Drugs. See specific drugs yalactosylation, of PLTs 142 Duffy blood group amma irradiation 1658 DNA analysis 7-CSI PCR-SSP el antigen-specific assay transfusion-induced autoantibodies senotyping ABO E blood group typing using P¢ East Asian population Duffy blood group eBDS fetal E blood group HBV Education HPA Volume 47, December 2007 TRANSFUSION 2363 SUBJECT INDEX mass-scale 18:40 neonatal . — ‘ a Germany sickle cell ... achitheineseibetniinaniiie ” cbinebiaies SS blood group genotyping 18:47 Hemoglobin-based oxygen carriers . ae sisenaasel .... 2098 blood utilization 28:152 Hemoglobinopathies ‘ ; = a 1552(1 parvovirus B19 donor screening 1775 Hemolysis Glycolipids 876 after PLT transfusion 1412 Glycolysis 1666 childhood AIHA ieee ae Glycoprotein Illa 2260 cord RBC units ‘ ' 1481 Glycoprotein V1 2057 Hemolytic anemia Glycosyltransferase 864 drug-induced wensssenennccn EE GM-CSI . 2133 fetal .... 911 Good manufacturing practices . 520, 1588 Hemolytic disease of newborn 2126 Grandparentage analyses 35 Hemophilia 8 Granulocytes ~— 969, 1268 Hemorrhage Granulocyte transfusions 2185 controlled, HBOC use in ‘ si , 2098 Gravity separation, of RBCs intracranial : ’ 8, 901 GVHD Hemostasis 4S:206, 374 lower incidence after CB transplant Hepatitis B core antigen 1809 pediatric . Setaecaaiadaadan Hereditary angiedema ; 1028 transfusion-associated, prevention of Herpesvirus 8 1550(1 HEX seveee 2098 H Hip replacement 379, 832, 1468 Half-sibship HIV Haplotypes, X-chromosome 1050 Brazilian donors and 97, 608 Haptoglobin gene 1948(L), 2315 multiplex NAI 1783, 1803 HBOC-201 ¥ ‘ 723, 2098 residual risk : 316, 529, 2011 ae ies 1162 1197, 1809 resistance In recipient ’ 1328(1 HBV rr . ; 1710 antigenemia 1162 HLA-A2-Ig-based artificial APCs 2143 duration in donors 1162 HLA/Cw typing 2322 HBc donor screening 1794, 1809 HLA-DR antibodies 154 multiplex NAT 1783, 1803 HLAs in Pakistan 74 alloimmune response £1522929 residual risk 316, 529 Class II 154 conditional silencing 18 in children 615 production after PBPCT 326 interassay correlation 1686 sensitization . 374 multiplex NAT 1783, 1803 typing ‘ ; 1405 residual risk csi 316, 529 H5N1 ... . . —_ residual risk for Chinese donors 2011 HNA-reactive neutrophil antibodies ..... 478 risk factors among Israeli donors 1189 Hodgkin's disease 2207 sequence analysis confirmation 1102(1 Hollow-fiber filtration system ; 2271 suspected transfusion-transmitted 1534 Hospitals. See also Blood center-hospital relationship Health-care issues 1733 Belgian Heart valve replacement 34] concentration of transfusion resources Hemagglutination inhibition test 1630 relationship with blood center 2S:106, 109, Hematocrit 114, 117 bleeding time and , 48:206 revenue, blood and 28:114 in blood volume calculation for children 212 satisfaction with blood center 2S:109 PLT transfusion trigger 48:206 tertiary-care, PLT transfusion triggers 206 seasonal variation 890 tissue oversight 185(k Hematologic recovery rate 817 tissue recall management plan 927 Hematology analyzers 1651 HPA la antibody 901, 1296 Hematopoietic progenitor cells HPA 1 alloantibodies 1363 autologous blood HPA 5b antibodies 901 postchemotherapy HPA 15b antibodies 901 autologous postchemotherapy HPA-13bw ... 1510 bacterial contamination HPA-immunized pregnancy 901 culture-positive HPAs 1637 infusion HPA-5 system 59 autologous blood HPBPCI , 1494 adverse events HLA antibody production 326 recovery from cord blood HPC grafts sterility testing DMSO-reduced 1268 Hematopoietic progenitor cell transplant recipients HPC mobilization of rare blood chemotherapy-based 629, 1447, 2153 Hematopoietic stem cell transplant HPCs Hemicolectomy in optimizinPBgP C collection , ; ... 1851 Hemodilution, acute normovolemic HPC , Re 781 Hemodynamics, during plasmapheresis HPCT, allogeneic ‘ 781 Hemoglobin Hp 1948(1 bovine Hp“ ; ; 2315 fetal H12-PEG-polyAlb i . ‘ 1254 2364 TRANSFUSION Volume 47, December 2007 SUBJECT INDEX HSCT bleeding complications Japanese Red Cross outcome Japanese repositories HTLV, residual risk JCAHO standards Human development, blood supply access and JK Human platelet lysate JK Human platlete antigen-la JMH blood group system HVN1 influenza Hydroxyethyl starch Hydroxyurea K4500 analyzer Hypercoagulability KATOIII cells Hyperleukocytosis K562 cell panel Hypersplenism K562 cells Hypocalcemia Kell blood group Hypotension antigens, high-prevalence leukoreducted PLTs and 110 autoantibodies from pediatric apheresis 183 DNA analysis pediatric autotransfusion 1503 fetal genotyping vasoactive mediators and 369(I KELnull and KELel Hypothermia 18:206 PCR-SSP Kidd blood group autoantibodies, transfusion-induced dentification, patient DNA analysis Idiopathic thrombocytopenic purpura renal allograft rejection gAl Kidney failiure gG Kinins gM KIRs gM B19 antibody Klebsiella pneumoniae mimigrant blood donors Knee replacement Immune deficiency Knops blood group system mmune hemolytic anemia, drug-induced KODE technology Immune response, tumor-specific Kx blood group mmunization mmunocompetence 1405, 1455 mmunoglobulin-like transcript | 1395 Labeling Immunohematology bar code tec hnology *S: 1205S, 1674 DNA-based technology error reduction FDA role in radiofrequency technology molecular methods standards for cellular therapy products phage display-based molecular methods proteins Leclercia adencarboxylata mmunomodulation, RBC transfusion Lectin binding mmunoselection Lenograstim mmunotherapy Lentiviral-based vector systems mpact-R analysis Leukapheresis mpedance cardiography in AMI ndian blood group system CD34+ cell yield ndirect antiglobulin test crossmatch good manufacturing practices nfants monocyte enrichment nfections, in thalassemia intermedia PBPC mobilizatioann d Influenza precursor dendritic cells nfluenza virus ukemia pandemic sukoencephalitis, acute hemorrhagic nformed consent ukoreduced RBC transfusions ntegrin antibodies postthaw storage Intention-to-treat principle in surgical patients NTERCEPT *ukoreduction nterferons COM.TEC cell separator nterleukins hypotension Intracranial hemorrhage postoperative infection and Intrauterine death universal prestorage Intrauterine transfusion whole-blood from sickle trait donors Intravednruog uusser s whole-blood plasma Investigation Leukoreduction system chambers rRALI Likelihood ratios transfusion-transmitted HC\ Lipid raft-associated proteins In vitro diagnostic products Liver disease lron, intravenous Locked nucleic acid Iron chelation therapy Lookback study Iron overload HBV 119 ISBT 128 HCV 615 ISBT/ICSH international workshops Lutheran blood group system 1630 Israeli donors LW antigen 1755 IVIG Lymphocyte subpopulation phenotyping 1691 Volume 47, December 2007 TRANSFUSION 2365 SUBJECT INDEX Lymphocytic choriomeningitis virus . NK cell processing Lymphoma 499, 1447 Norway NovoSeven, “off-label usage M NSAIDs Magnetic cell sorting program Nucleated RB(¢ quantification MAIEA assay 1306 Null alleles MAIPA assay 363 Null phenotype MALDI-TOF MS 1099(1 Male genetic transmission 918 Oo McLeod phenotype : 299 Observational studies 1115 Medical device companies 1098(I Occupational exposure predonation screening questions 949(1 MEIA assay 1686 Onyx analyzer 1651 Melphalan , 115 Open-heart surgery 953 Mesenchymal stromal cell propagation 1426 1436 OrbiSac system 126 1555(1 Meta-analysis Orientia tsutsugamushi 240 intravenous iron 1905 Orthostatic hypotension 24 of leukoreduced blood transfusions 573, 1946(1 of PLT dose seaeagib ; Metabolic problems, in thalassemia intermedia PAGGS-M MH¢ expression PAR4 1054, 17 } Microbial detection methods Paracetamol Microbiologic screening test, false-reactive results Parentage analysis 1050 Microcalorimetry Paroxysmal cold hemogiobinuria Microchimerism PARV4 Microparticles, storage-generated PARV5S Minor histocompatibility antigens Parvovirus B19 Minority blood donation improvement blood transfusion and Misfolded protein diagnostic assay DNA Misssense mutations 1306 donor screening Mithramycin A .... ' 842 inactivation Mitomycin C-associated thrombotic microangiopathy 1263 PAS-IIIM Mobilization Passenger lymphocytes, donor-derived CD34 cells Passive transfusion rituximab-ESHAP regimen Pasteurella multiocida bacteremia Molecular assays Paternal lineage analysis guidelines/ proficiency testing Paternity testing in immunohematology exclusionary power Monocyte enrichment single-parent Mononuclear cells Pathogen inactivation 2180(t Mortality. See Death efficacy 1 106(E 1125 1896 Mouse model parvovirus B19 1765 M-sol additive solution Pathogen reduction technology. See also Pathogen inactivation Multicenter studies 644, 2011 Photochemical treatment Multiple myeloma 115 PCT with amotasalen and UVA 434 Murine model sa 11, 1418 riboflavin and light 240 Muscle tension technique Pathology residency programs 1930 Mutations PBMNCs 1691 B-related subgroup PBPCs inactivating collection 230 1234 XK cryopreservation Myeloma-associated renal failure mobilization PBPC transplantation alloimmunization risk NAI CD3 T-cell depletion anti-HBc engraftment prediction automated multiplex PCR false-reactive results allele-specific polymorphism strategy HB\ 1162 CMV DNA HC\ 1102(1 cytomegalovirus DNA minipooled 883 1102(L), 1197, 1775 parvovirus B19 DNA multiplex 1803, 2011 RHD typing parvovirus B19 1775 PCR-ASP analysis viral infection residual risk : 529 PCR-RFLP National Blood Collection and Utilization Surv 366(E PCR-SSP blood group typing National Marrow Donor Program L1O1(1 Pediatric patients Neonatal alloimmune thrombocytopenia 6(E 1363 1488, 1510 apheresis complications Neonatal anemia 18:10 autotransfusion for elective surgery Neonatal thrombocytopenia . ; 59 blood volume calcuation Neuroacanthocytosis . 299 GVHD Neutropenia 2185 HCV in Neutrophil chemotaxis ¥ 1395 hemolysis after PLT transfusion Neutrophil-specific antibodies ... , .. 478, 545, 559 PBP( cryopreservation Nitric oxide 4S8:206 rFVila usage 2366 TRANSFUSION Volume 47, December 2007 SUBJECT INDEX Pegfilgrastim utilization pH In Vivo recovery parvovirus B19 inactivation 1765 whole-blood-derived PLI 1666, 1889 Platelet contamination Phage display-based molecular methods proteins 18:89 AABB criteria Phagocytosis abnormal appearance FCy receptor mediated 290, 2250 collection method comparisons PLI 442, 2161 detection of RBC 2161 detection proficiency testing Pharmaceutical industry 1098(1 vross Phosphatase 2161 Leclercia adecarboxylata Phosphate-buffered saline 2242 low levels of bacteria Photochemical treatment 216 parvovirus B19 inactivation 062 with amotosalen and UVA bbb Pasteurella multocida 984 parvovirus B19 inactivation 1062 progress assessment OF PLT quality 653 Staphylococcus epidermidis biofilms 143 PLTs in plasma 1896 Staphylococcus lugdunensis 1390 Photophoresis 2276 transfusion-transmitted infections 206 Physician transfusion practices S-132 Platelet count Pittsburgh centralized transfusion model 2S:164 1utomated 1651 Placental blood 22/1 bleeding time and 18:206 Plasma-clotting proteins 18:206 frequent plateletpheresis and 1601 Plasma exchange, therapeutic. See Therapeutic plasma exchange G-CSF-induced thrombocytopenia and hypersplenomegaly 4] Plasmapheresis low 1700 ANP in transfusion trigger 48:206 201, 206 light-chain removal as transfusion trigger 801 seasonal variation in H¢ Platelet disorders, qualitative 8 Plasma products Platelet factor 4 1099(1 ADAMTS13 in Platelet function cytomegalovirus DNA in aspirin 1 S:206, 6 HSN1 influenza virus and bleedtiimne gan d 18:206 parvovirus detection in in extracorporeal bypass, skin temperature and 18:206 rickettsial inactivation Platelet pH 1666 Platelet activation Platelet phagocytosis 161 cytokine release and Plateletpheresis during storage asymptomatic donors Platelet additive solutions bacterial detection Platelet alloimmunization with COM.TEC cell separator Platelet cold agglutinins frequent Platelet concentrates resident cell content bacterial contaminated (See Platelet contamination safety profile bacterial detection (See Bacterial detection Platelet proteins, alterations during storage bacterial infections associated with 1206 Platelets bacterial testing 192(1 aggregation, painkillerasn d buffy-coated 666, 1099(1 baboon concentrates (See Platelet concentrates coated cryopreserved 18:206 Platelet storage donor painkiller usage and 6 activation during fresh 418:206 agonist-induced responses frozen 18:206 ilterations during gamma-irradiated 653 glycoprotein III a 260 glycoprotein Illa 2260 hemostatic potentiaaln d 205 hyperconcentrated 1488 interuption of agitation 955 leukoreduced bbb, 9B lesions 1099(1 for nonsurgical bleeding diathesis $8:206 long-term retrigeration pathogen inactivation microparticles pH in M-sol photochemical treatment pH platelet activation and cytokine release prestorage pooling posttransfusion purpura seven-day preserved Staphylococcus epidermidis biofilms prestorage pooling without agitation proactive administration for AAA Platelet substitutes quality of 45:206, 653 Platelet transfusions radiolabeling procedure 946(1 blood data collection reports recovery 2305 hemolysis after refractoriness 4/4 indications screening 1106(E prophylactic 188 t 301 single-donor 192(t refractoriness storage (See Platelet storage survival 1S:206 survival/function, in Bernard-Soulier syndrome 103 trigger 18:206 transport 1666 triBgSg ers l 201 06, 1700 trehalose-stablized freeze-dried outdated 672 in United States 385 Volume 47, December 2007 TRANSFUSION 2367 SUBJECT INDEX Polymorphisms collection allele-specific PCR strategy 2110 automated double . 995 Dombrock blood group system blood data collection reports 366(E) nonexofacial 2189 safety profile 1002 SNPs - . 147, 1337(E), 1369 RBC exchange, prophylactic 1494 Polyneuropathy, demyelinating 2072 RBC membranes Polyolefin bags ; 1241 carbohydrate changes during storage 966 Postoperative blood salvage 362( I remodeling in storage 1212 Postoperative infections 573, 1945(1 synthetic glycolipid modifications 876 Predonation screening phagocytosis 2161 in Canadia 949(L), 1595, 1794 s Chagas antibody ELISA 90 additive solutions 680 DNA typing 18:10 loss (See Bleeding false-reactive results pecuiclin 80 from placental blood 2271 high-throughput DNA analysis 736 rare = = arene 754(E medication usage . 67 reagent for DNA analysis, QA of 18:73 multiplex NAT 1803 resuspension in AS-3 680 parvovirus B19 iia rickettsial inactivation in .. 240 questions 949(I senescence 725 RHD typing .. snsede 1350 storage 966 uniform donor history questionnaire 1595, 1990 yield 997 Pregnancy RBC transfusions anti-Fy* alloimmunization in 1858 alloimmunization 2066 HPA-immunized 901, 1296 auto- and alloantibodies from 813 Pregnancy test, posttransfusion false-positive 788 blood data collection reports 366(E Premedications on 1089 D+, detection anti-D in D- in recipients 2197 Prenatal laboratory evaluation .. 2170(I in elective surgery . 1468 Pretransfusion bedside check ee HIV-RNA-positive/anti- HIV-negative donor 1328(1 Primate model 162, 949(L), 2223 immunomodulary effects 1691 Prion proteins siileiuliai 1419, 2223 large-volume, in cardiac surgery 2081 Procaryote recombinant Lu 1630 leukoreduced 1691 PROCLEIX ULTRIO assay 1783 for major spine surgery ; 1022 Professionalism 1733 for nonsurgical bleeding diathesis 48:206 Proficiency tests 18:79, 95 triggers 48:206 Progenitor cell automated collection 12 34 in United States 385 Prognosis 2207 unmodified 1691 Prophylaxis in vivo TGF-B1 induction platelet transfusions 188(E), 801, 1700 RBC units, cord . 1481 RBC exchange 1494 RBC volume calculation, for pediatric transfusion 212 Propionibacterium acnes 1643 Recombinant anti-D 306 Prospective cohort studies 1115 Recombinant C1 -inhibitor 1028 Protein A immunoadsoption therapy 1263 Recombinant Lu 1630 Protein C, activated 1880 Recombinant proteins ‘ . 18:85 Proteomic profiling 1221 REDS-II Leukocyte Antibody Prevalence Study (LAPS PRP, abnormal appearance 1961 Regulatory T cells a= sdaeietsibibicese 1418 Renal failiure _— ” Pseudoxanthoma elasticum Reporting, suspected transfusion-transmitted HC\ Public health notification Research questions Pulmonary hypertension Retransfusion, of filtered shed blood Pulmonary reactions, neutrophil-specific antibodies and Retrospective analysis Purpura cohort studies autoimmune thromboc ytopenic spine surgery transfusion practice 1022 posttransfusion rFVIla 8 PVC bags Rh(D) alloimmunication 1959 I Rh blood group system Q anti-D in D+ individuals ° O09 Quality control 2S:173337, ,113 4 DNA genotyping 18:17, 1337 D variants 471 R D variants in Chinese population 171 Radiofrequency identification technology 2S8:125, 763, 946(1 fetal genotyping 2126 Random grandparents not excluded 35 genotyping 18:47 Randomization, in clinical trials 1753 PCR-SSP typing ‘ —— Randomized controlled trials, meta-analysis of PLT dose 4164 phenotypes 18:60, 736, 1616 Randomized crossover study, automated PBP( 1234 serologic typing 18:17 Rare blood 754(E), 781, 1630 transfusion mismatch 2197 Rat model 1254 RHCE gene 486 RBC additive solutions 680, 2242, 227 RHD gene RBC alloimmunization 781, 1959(E) deletions 852, 1552(L) RBC antibodies 781 DNA analysis 852 RBC antigens mosaicism/chimerism 715 donor genotyping operational issues . 18:69 novel alleles 858 phenotypes 18:60, 736, 1616 quantitation 715 autoantibodies . 50, 2189 typing 1350 2368 TRANSFUSION Volume 47, December 2007 SUBJECT INDEX weak D detection RhD zygosity inactivation Rh hemolytic disease Staphylococcus lugdunensis rHuEPO Stem cell transplants Riboflavin and light, inactivation of blood products Sterility testing, HPCs Rickettsia inactivation storage Rituximab extended, of frozen-thawed AS-5 RBCs 680 Rituximab-ESHAP regimen microparticles 1880 RNA inhibition platelet (See Platelet storage RNA transfection RBC RT-PCR RBC membrane remodeling RV-PBS( short-term liquid Staphylococcus epidermidis biofilms Ss whole-blood SABM abstracts from 2006 Annual Meeting whole-blood plasma Safety Storage facilities of automated collection Streptococcus SANQUINIS bar code labeling Structure-function studies blood center-hospital relationship and Sulfhydryl groups blood supply access Surgery error prevention arthroplasty 379, 832 hemovigilance cardiac 2081 H5N1 influenza virus and elderly, blood utilization patterns 82 hydroxyurea in thalassemia major elective 03 improving donor health profile leukoreduced transfusions for intravenous iron therapy 905 open-heart monitoring 11L10(E pediatric pathogen inactivation 2180(1 spinal uniform donor history questionnaire 1990 tranfusion complications weak D phenotypes and 1616 transfusion practice SAGM additive solution Sweden 2S:169, 80, 2017 Saline-adenine glucose-mannitol systematic reviews 4 Sampling, culture-based bacterial detection SCID Scottish National Blood Transfusion Service TACO Seasonal variation, HCT TA-GVHD Sema7A in immunocompetent patients Sepsis, residual risk posttransfusion purpura Seroconversion, cytomegalovirus prevention Serology testing laiwanese population AIHA in childhood and TaqMan PCR cytomegalovirus seroconversion faqScreen multiplex test drug-induced immune hemolytic anemia I-cell depletion D typing PCR analysis 691 HB\ lfemperature Serum free light-chains bleeding time and 18:206 sFasl clotting time and 18:206 sHLA-I seasonal variation, HCT and 890 Short tandem repeats WB cooling plates 2038 autosomal whole-blood storage 2050 half-sibships ferminology standards, for cellular therapy products l X-linked 1050 PGF-B1 1481 shRNAs Thai population 2315 Siblings rhalassemia intermedia 792 Sickle cell anemia ao1l Thalassemia major ; 1919 Sickle cell disease 1S:10, 2089 rheory of Planned Behavior 1006 Sickle cell trait rherapeutic apheresis 1963 Simian foamy virus 162, 949(1 Therapeutic plasma exchange Single-nucleotide transitions 1014 for acute hemorrhagic leukoencephalitis Skin temperature 4$:206 ADAMTS13 in SNPs 1337(E), 1369 'TP-HUS outcome Social science, donor recruitment/retention and 1999 Thrombin 2057 Solid malignancy alloimmunization risk 2066 Thrombocytopenia Southeast Asian population 315 autoimmune 199 Spanish popuulation 948(1 G-CSF-induced with hypersplenism 11 Spectra apheresis machine 234 H12-PEG-polyAlb treatment 1254 Spine surgery 022 nonsurgical bleeding diathesis 48:206, 1744(I Splenomegaly 7Q9 prophylactic PLT transfusion 164, 1700 Staphylococcus aureus lhrombocytopenic purpura-hemolytic uremic syndrome. See TTP-HUS detection 643 Thromboelastography 2057, 2098 inactivation 1896 §-Thromboglobulin 1099(1 Staphylococcus epidermidis Thrombotic microangiopathy, mitomycin C-associated 1263 biofilms 143 TIGRIS system 1783 Volume 47, December 2007 TRANSFUSION 2369 SUBJECT INDEX lime dependence, culture-based bacterial detection Iravel deferral caialoibaninn limersal sastibeaniond [Treatment allocation, in clinical trials lissue recall management plan Irehalose-stablized freeze-dried outdated platelets ... [-lymphocytes lrima Accel platletpheresis device 1042 cytotoxic Trypanosoma cruzi posttransfusion purpura ...... antibody detection [TNF-a inactivation ‘ ‘ folerance transfusion-acquired infection Total hip arthroplasty sk —— Total knee arthroplasty 379, 1468 rTP, HIV-related rRALI rTP-HUS female donor risks 559(E), 563(5 HLA Class II antibodies 154 U investigation and donor management 1118 Ultrarapid freezing aaewere! neutrophil-specific antibodies 559(f Umbilical cord blood. See Cord blood policies/ practices 1679 Uncontrolled-rate freezing 2202 risk reduction 559(E), 563(1 Uniform donor history questionnaire 1990 surveillance 599 United States. See also American Red Cross TACO and .... blood collection and transfusion 385 ransfusion chelation therapy potential blood donor pool 1180 Iransfusion costs 17 rRALI policies/ practices stecanonieiin 1679 lransfusion medicine UVA with amotosalen. See Amotosalen with UVA curriculum content proposal 1930 hemovigilance V policies Vasoactive mediators Transfusion reactions Vasovagal donor reactions acute, classification of vCJD. See Creutzfeldt-Jacob disease, variant documentation Viruses. See specific viruses febrile nonhemolytic 1089 Vitrification residual risk 1134, 2011 Vw septic, residual risk 1134, 1 ransfusions W complications eee 25:184 Wales, blood center hospital relationship 2S:158 computerized decision support interventions 228 Water drink, vasovagal donor reactions and 1524 documentation WBC antibodies 599 inappropriate, reducing WBC chimerism 781 leukoreduced WBC count 2233 for massive bleeding Whole-blood donors 890, 895 parvovirus and Whole-blood plasma, leukodepleted 460 pathologies requiring Whole-blood storage 2038, 2050 premedications Whole-blood units, sickle trait £922252 9 radiofrequency identification technology Wound healing 6/72 for thalassemia intermedia vs. hydroxyurea in thalassemia major lransfusion services X-chromosome genotypes 276 bedside error reduction X-chromosome haplotypes 1050 blood shortages XK gene product 299 for influenza pandemic X-linked STRs 1050 role of XT 2000i 1651 lransfusion-transmitted infections blood donation archive repository detection methods 1 1LO6(E Y-chromosome STRs parvovirus B19 donor screening 1775 Yield prevention 1125, 2180(t CD34+ cells prevention of cytomegalovirus 1955(5 RBCs reporting/investigating 1534 WB residual risk 929, 2011 Y-lineage transmission risk from Brazilian donors 608 Trypanosoma cruzi 40 Transport, PLT concentrate 1666 [Trauma 5Q 2370 TRANSFUSION Volume 47, December 2007